Date: 2011-01-09
Type of information: R&D agreement
Compound: use of Silence’s proprietary DBTC delivery system for miRagen’s novel microRNA- (miRNA-) based therapeutics
Company: Silence Therapeutics (UK) miRagen Therapeutics (USA)
Therapeutic area:
Type agreement: R&D
Action mechanism: DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel lipid-based formulation that functionally delivers short interfering RNA (siRNA) to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.
Disease: undisclosed
Details: Silence Therapeutics has signed an agreement with miRagen Therapeutics to assess the delivery potential of Silence’s proprietary DBTC delivery system with miRagen’s novel microRNA- (miRNA-) based therapeutics. MiRagen is a pre-clinical stage biopharmaceutical company founded to develop innovative miRNA-based therapeutics for the treatment of cardiovascular and muscle disease. Under the terms of the agreement, miRagen will provide Silence with specific miRNA sequences, which Silence will formulate with its proprietary DBTC delivery system in order to develop multiple candidate drugs. MiRagen will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation.
Financial terms: Financial terms of the collaboration are not disclosed.
Latest news:
